Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 5 months ago
What's hot at #AHA23?Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the late-breaking science data from AHA Scientific Sessions 2023.They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.Trials Covered00:20 - DAPA… View more

Anticoagulation

Standards & Guidelines
RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients
Author(s): Harald Thune Jorstad Added: 2 years ago
In this video, Dr Harald Thune Jorstad (Academic Medical Center, Amsterdam, NL) discusses the findings of RESPONSE-2, a randomised trial aiming to investigate the long-term outcomes of community-based lifestyle interventions in coronary artery disease (CAD) patients. The study showed that at 3 years follow-up, the benefits of 1 year of nurse-coordinated referral to community-based lifestyle… View more

Anticoagulation
View from the Thoraxcenter - What's hot at ESC 2019
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 4 years ago
Dr Nicolas van Mieghem & Dr Joost Daemen preview the late-breaking trials at the upcoming ESC 2019 congress. View more

Anticoagulation
Dominick J Angiolillo
Research Area(s) / Expertise:

Thrombosis, embolism & bleeding

Intervention

Coronary Artery Disease and Myocardial Infarction

 Job title: Professor & Chief
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology.Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology. In 2004, Dr… View more
ESC 22 Late-breaker Discussion: The INVICTUS Trial
Author(s): Harriette Van Spall , Ganesan Karthikeyan Added: 1 year ago
ESC Congress 22 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) invited Dr Ganesan Karthikeyan (All India Institute of Medical Sciences, IN) to share the latest data from the INVICTUS trial (NCT02832544). This randomized, open-label, non-inferiority trial compared rivaroxaban (Xarelto, Bayer) versus standard vitamin K antagonists (VKA) (Warfarin) therapy in 4,500 patients… View more

Anticoagulation

Electrophysiology & Arrhythmia
View from the Thoraxcenter: ACC.22 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
Learn about the key take-home messages from ACC.22 with View from the Thoraxcenter hosts, Professor Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this succinct review video, they summarise the top late-breaking science trials and share their take on how the new data can be translated into practice. Trials covered in detail include: 00:29: PACMAN AMI:… View more

Anticoagulation

Vascular Disease and Surgery
Marco Valgimigli
Job title: Deputy Chief of Cardiology
Prof Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland.He obtained his medical degree from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at… View more
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Author(s): Naima Maqsood , Jeff Healey Added: 4 months ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more

Anticoagulation

Electrophysiology & Arrhythmia
View from the Thoraxcenter: What's Hot at ACC.24?
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 3 weeks ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,… View more

Anticoagulation

Heart Failure
ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib
Author(s): Afzal Sohaib Added: 1 year ago
ESC Congress 2022 — In this short and practice-focused review, Dr Afzal Sohaib,Electrophysiologist atBarts Health NHS Trust, shares his thoughts on the top 3 trials that will impact his practice. Trials covered in detail include: 00:18:eBRAVE-AF: eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial 01:34:CAPLA: Catheter ablation for persistent… View more

Anticoagulation

Imaging & Diagnostics